Abstracts tagged "gout"

Abstract Number: 2012 • ACR Convergence 2024
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
Orrin Troum¹, John Botson², Fang Fang³, Katie Obermeyer³, Supra Verma³ and Brian LaMoreaux⁴, ¹Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, ²Orthopedic Physicians Alaska, Anchorage, AK, ³Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase, infused every 2 weeks over ≥2 hrs, lowers serum urate (SU) in patients with refractory gout. Decreasing infusion time is expected to improve…
Abstract Number: 2559 • ACR Convergence 2024
Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis
Brooke Kelly¹, Gregory Gamble¹, Anne Horne¹, Anthony Doyle¹, Jill Drake², Opetaia Aati¹, Chang-Nam Son¹, Ramanamma Kalluru³, Kieran Latto¹, Lisa Stamp⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, New Zealand, ³Health New Zealand, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. The aim of…
Abstract Number: 0142 • ACR Convergence 2024
The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis
Nidaa Rasheed¹, kHALED ABDULLAH² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Gout is characterized by chronic inflammatory arthritis caused by the deposition of monosodium urate crystals and leads to increased risk of complications, such as…
Abstract Number: 0283 • ACR Convergence 2024
Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model
Jaymin Shah, Elaine Chan and Dmitri Lissin, Scilex Holding Company, Palo Alto, CA
Background/Purpose: Patients receiving colchicine for prophylaxis of gout flares are at risk for dose-related gastrointestinal toxicity (nausea, vomiting, diarrhea, abdominal pain) if they have pre-existing…
Abstract Number: 1088 • ACR Convergence 2024
Prospective Evaluation of Carotid Atherosclerosis, Urate Deposits and Inflammation After One Year of Treatment in Newly Diagnosed Gout
Cristina Rodríguez Alvear, Agustín Martínez Sanchís, Irene Calabuig Sais and Mariano Andrés, Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain
Background/Purpose: Carotid atherosclerosis is prevalent in patients with gout. A prior cross-sectional study at our hospital demonstrated an association between tophi and positive Power Doppler…
Abstract Number: 1289 • ACR Convergence 2024
Gout Education for Primary Care Providers: A Scoping Review
Madeline O’Sullivan¹, Michael Battistone², Gary Kunkel³, Kalani Raphael¹, Lydia Howes⁴, Naomi Schlesinger¹ and Andrea Barker², ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA, Salt Lake City, UT, ³University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁴University of Utah, 10 N 1900 E, UT
Background/Purpose: Gout is the most common inflammatory arthritis. Despite widespread availability of effective therapies and management guidelines from ACR and EULAR, many gout patients remain…
Abstract Number: 2013 • ACR Convergence 2024
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
Lenka Hasikova¹, Petr Kozlik², Kveta Kalikova³, Petr Dusek⁴, Marketa Pavlikova¹, Blanka Stiburkova⁵ and Jakub Závada⁶, ¹Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Neurology and Centre of Clinical Neuroscience and Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…
Abstract Number: 2560 • ACR Convergence 2024
Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study
Hilde B Hammer¹, Lars F Karoliussen¹, Lene Terslev², Espen A. Haavardsholm³ and Tillmann Uhlig¹, ¹Diakonhjemmet hospital, Oslo, Norway, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway
Background/Purpose: Ultrasound (US) is sensitive for detecting monosodium urate (MSU) crystal depositions in gout, described as double contour (DC), tophi and aggregates. Depositions decreased during…
Abstract Number: 0178 • ACR Convergence 2024
Are Participants in Gout Clinical Trials Representative of People with Gout in the General Population?
Jendy Liu, Gregory Gamble and Nicola Dalbeth, University of Auckland, Auckland, New Zealand
Background/Purpose: Ensuring study participants are representative of the general population is important to ensure that efficacy and safety findings of clinical trials are generalizable in…
Abstract Number: 0355 • ACR Convergence 2024
Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Vibeke Strand¹, Puja Khanna², Alan Kivitz³, Nana Kragh⁴, Aletta Falk⁵, Rehan Azeem⁶, Hugues Santin-Janin⁷ and Herbert Baraf⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of Michigan, Ann Arbor, MI, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Sobi, Stockholm, Sweden, ⁶Sobi Inc., Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Center for Rheumatology and Bone Research, Wheaton, MD
Background/Purpose: Patients (pts) with gout have impaired health-related quality of life (HRQoL) relating to acute or chronic inflammation from elevated serum uric acid (sUA) levels.…
Abstract Number: 1089 • ACR Convergence 2024
Endothelial Activation in Gout
Michael Toprover¹, Binita Shah², Kamelia Drenkova², Michael Pillinger³ and Michael Garshick⁴, ¹New York University Langone Health, New York, NY, ²NYU Langone Health, New York, NY, ³New York University Grossman School of Medicine, New York,, NY, ⁴NYU Langone Health, Tenafly, NJ
Background/Purpose: Gout is the most common inflammatory arthritis and is associated with increased cardiovascular (CV) disease and cardiovascular mortality. Our prior studies have suggested that…
Abstract Number: 1293 • ACR Convergence 2024
Educational Quality Improvement (QI) Project to Improve Inpatient Purine Restricted Diet Order Placement for Patients Admitted with Gout Flares
OKEOGHENE AKPOIGBE¹, COMFORT ANIM-KORANTENG², BETTINA ESCOLANO³, NI NI LWIN¹, JOANNA PANGILINAN¹ and Amanda Sammut⁴, ¹New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, ²New York City Health and Hospitals/Harlem in Affliation with Columbia University, Bronx, NY, ³New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, ⁴New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY
Background/Purpose: Gout is a chronic, but treatable, inflammatory disease characterized by intermittent flares involving the deposition of monosodium urate crystals in and around joints. It…
Abstract Number: 2014 • ACR Convergence 2024
Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial
Anna Kretova¹, Carlijn Wagenaar¹, Wendy Walrabenstein², Daisy Vedder², Dirkjan van Schaardenburg² and Martijn Gerritsen¹, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: An unhealthy diet is an important modifiable risk factor for hyperuricemia and gout and is also associated with obesity and metabolic syndrome (MetS), known…
Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Natalie McCormick¹, Amit Joshi², Robert Terkeltaub³, Tony Merriman⁴, Matthew Nayor⁵, Chio Yokose⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Waltham, MA, ⁷Massachusetts General Hospital, Lexington, MA
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…
Abstract Number: 0206 • ACR Convergence 2024
Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout
May Shuen Tang, Frank Sen Hee Tay, Amelia Santosa, Shikha Kumari, Pamela Lim, Htet Htet Aung, Su Zin Thinn, Peter Cheung and Manjari Lahiri, National University Hospital, Singapore, Singapore
Background/Purpose: Gout is sub-optimally managed with under-prescribed urate lowering therapy (ULT) leading to frequent flares, increased healthcare utilization and cost.To study the burden of gout…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.